RaySearch and Mevion - A synergy of innovation transforming proton therapy

STOCKHOLM, Oct. 2, 2023 /PRNewswire/ -- RaySearch Laboratories AB (publ) is proud to announce the continued commitment with Mevion Medical Systems, the leading global provider of compact proton therapy solutions, to develop new proton therapy solutions in support of current and emerging technologies. Together RaySearch and Mevion re-imagine novel solutions to advance the use of new proton therapy technologies and empower medical providers to rapidly and efficiently bring next-generation proton therapy services to their patients.

The collaboration leverages both companies’ domain expertise in the advancement of innovative solutions for HYPERSCAN IMPT, adaptive therapy, proton arc therapy, and FLASH proton therapy. Key development areas are:

• RayStation®* treatment planning system: RaySearch is optimizing treatment planning algorithms to advance the use of the HYPERSCAN PBS technology. One of the upcoming goals is to further develop existing algorithms to support upright treatments of the new ultra-compact MEVION S250-FIT proton therapy platform.

• RayCare®* oncology information system: RayCare is designed to efficiently support complex and advanced clinical processes such as adaptive therapy. Mevion has integrated in-room diagnostic CT imaging on the MEVION S250i and MEVION S250-FIT platforms to optimize the use of adaptive therapy. RaySearch and Mevion will join forces to streamline and standardize the delivery of adaptive proton therapy treatments by integrating these technologies.

• Proton arc therapy: Arc therapy is an emerging proton therapy treatment delivery technique that optimizes rotational techniques of a gantry or upright patient positioner to conform and precisely target a tumor from multiple angles. Mevion technology has unique capabilities with the HYPERSCAN PBS technology with pMLC, fast energy switching, and integrated robotic motion control capabilities. RaySearch is developing treatment planning algorithms in RayStation to use these advanced technologies.

• FLASH proton therapy: FLASH proton therapy is an investigational solution that delivers a high dose in a short period of time with the goal of substantially reducing treatment times and minimizing damage to healthy tissue and critical organs. RaySearch and Mevion are combining their strengths to enhance the accessibility and efficiency of FLASH, while facilitating its transition from research to clinical application.

Tina Yu, Ph.D., CEO and President of Mevion Medical Systems, says: “The synergy between Mevion Medical Systems and RaySearch Laboratories continues to redefine the landscape of cancer care. The united strength of our collaborative partnership is accelerating the deployment of emerging proton therapy developments. We are committed to breaking down technological and clinical access barriers to superior proton therapy technology.”

Johan Löf, founder and CEO, RaySearch, says: “RaySearch’s expertise in oncology software and Mevion Medical Systems’ latest technological advancements will continue to bring innovation in the proton therapy field and we look forward to working together with Mevion to further advance proton cancer treatments.”

CONTACT:

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/raysearch-and-mevion--a-synergy-of-innovation-transforming-proton-therapy-301945001.html

SOURCE RaySearch Laboratories

Company Codes: Bloomberg:RAYB@SS, ISIN:SE0000135485, RICS:RAYB.ST, Stockholm:RAYB, Stockholm:RAY-B, Stockholm:RAY-B.ST